Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.
暂无分享，去创建一个
G. Giaccone | S. Steinberg | M. Raffeld | D. Gandara | R. Salgia | E. Vokes | E. Szabo | S. Khozin | L. Doyle | U. Guha | L. Xi | Anish Thomas | A. Rajan | C. Carter | K. Reckamp | B. Gitlitz | S. Koehler | C. Brzezniak | C. Keen | Christina E. Brzezniak | Corrine Keen